Hadjadj S, Fanelli A, Torremocha F, Maréchaud R
Service de médecine interne endocrinologie et maladies métaboliques Camille-Guérin, CHU Poitiers, BP 577, 86021 Poitiers.
Arch Mal Coeur Vaiss. 2001 Aug;94(8):928-32.
Type 2 diabetes mellitus is the main cause of increase in patients suffering from end-stage renal failure in France. We performed an observational study of the change in renal function of type 2 diabetic patients, attending our diabetology clinic. Clinical and biological data were regularly entered in an informatic database (Pénélope, Poitiers University Hospital). We prospectively followed 351 type 2 diabetic patients (age at diagnosis: 40 to 75 years), for 32 months (extremes: 1-120). Renal function was graded in 4 stages according to plasma creatinine and urinary albumin excretion (UAE) determined by nephelometry on random urinary sample: absent (UAE < 20 mg/L et creatinine < 150 mumol/L), incipiens (UAE 20 to 200 mg/L and creatinine < 150 mumol/L), established (UAE = 200 mg/L et creatinine < 150 mumol/L) advanced (creatinine = 150 mumol/L). Glycated haemoglobin (HbA1c) was determined by HPLC. Systolic/Diastolic Blood Pressure (SBP/DBP) was measured with a mercury sphygmomanometer. We defined renal events as the change from one stage of nephropathy to a higher one. A total of 351 type 2 diabetic subjects were studied: 194 men/157 women mean age 63 +/- 11 years, mean diabetes duration 10 +/- 9 yr. At baseline, 206 patients had no nephropathy, 98 incipient nephropathy, 28 established nephropathy and 19-advanced nephropathy. Baseline stage of nephropathy was related to SBP (p < 0.0001), DBP (p = 0.0002), diabetes duration (p = 0.0064) but not HbA1c (p = 0.2182) or sex (p = 0.4794). Among those 332 subjects without baseline advanced nephropathy, 134 progressed in nephropathy. Progression of nephropathy was not related to the presence of hypertension (SBP/DBP > or = 160/95 mmHg) (log-rank = 0.22; p = 0.6377). Conversely, patients with a poor glycaemic control (HbA1c > or = 10%) had a worse renal-event free survival (log-rank = 4.89; p = 0.0269). Glycaemic control is a risk factor for the progression in nephropathy of type 2 diabetic patients.
2型糖尿病是法国终末期肾衰竭患者人数增加的主要原因。我们对在我院糖尿病门诊就诊的2型糖尿病患者的肾功能变化进行了一项观察性研究。临床和生物学数据定期录入信息数据库(佩内洛普,普瓦捷大学医院)。我们前瞻性地随访了351例2型糖尿病患者(诊断时年龄:40至75岁),为期32个月(范围:1 - 120个月)。根据随机尿样经比浊法测定的血肌酐和尿白蛋白排泄量(UAE)将肾功能分为4期:无肾病(UAE < 20 mg/L且肌酐 < 150 μmol/L),早期肾病(UAE 20至200 mg/L且肌酐 < 150 μmol/L),确诊肾病(UAE = 200 mg/L且肌酐 < 150 μmol/L),晚期肾病(肌酐 = 150 μmol/L)。糖化血红蛋白(HbA1c)通过高效液相色谱法测定。收缩压/舒张压(SBP/DBP)用汞柱血压计测量。我们将肾脏事件定义为从一个肾病阶段进展到更高阶段。共研究了351例2型糖尿病患者:194例男性/157例女性,平均年龄63 ± 11岁,平均糖尿病病程10 ± 9年。基线时,206例患者无肾病,98例有早期肾病,28例有确诊肾病,19例有晚期肾病。肾病的基线阶段与收缩压(p < 0.0001)、舒张压(p = 0.0002)、糖尿病病程(p = 0.0064)有关,但与糖化血红蛋白(p = 0.2182)或性别(p = 0.4794)无关。在这332例无基线晚期肾病的患者中,134例肾病有进展。肾病进展与高血压(收缩压/舒张压≥160/95 mmHg)的存在无关(对数秩检验 = 0.22;p = 0.6377)。相反,血糖控制不佳(HbA1c≥10%)的患者无肾脏事件生存期更差(对数秩检验 = 4.89;p = 0.0269)。血糖控制是2型糖尿病患者肾病进展的一个危险因素。